Oct 2026· Breast Cancer· Vol 18, pp. 1-18· 0 citations· 38 references
Medicine
TL;DR
A 16-gene M2 macrophage–related signature (M2MMS) was identified that stratified patients into subgroups with distinct survival outcomes in both cohorts and provides a basis for risk stratification and mechanistic investigation.
Abstract
Purpose Tumor-associated macrophages (TAMs), particularly the M2-like phenotype, are central regulators of breast cancer progression; however, clinically applicable models capturing their functional heterogeneity and biological mechanisms remain limited. Patients and Methods We integrated single-cell RNA sequencing, spatial transcriptomics, and bulk RNA-seq data to construct an M2 macrophage–centered gene landscape. A machine learning framework based on 10-fold cross-validation was used to develop a prognostic signature in the TCGA-BRCA cohort (training set), with external validation in the independent GSE96058 cohort. Immune infiltration, genomic instability, pathway activity, and cell–cell communication were analyzed. KLF4 was examined in breast cancer cells and macrophages using qRT-PCR, Western blotting, siRNA-mediated knockdown, and a Transwell co-culture system. Results We identified a 16-gene M2 macrophage–related signature (M2MMS) that stratified patients into subgroups with distinct survival outcomes in both cohorts. High-risk tumors showed M2 macrophage enrichment, an immunosuppressive microenvironment, elevated genomic instability, and activation of E2F and MYC proliferative programs. Cell–cell communication analysis identified MDK–NCL as a dominant tumor–TME signaling axis. KLF4 was upregulated in breast cancer cells and in macrophages after co-culture, and silencing KLF4 attenuated CD206 induction, indicating that KLF4 is functionally involved in tumor cell–induced M2-like polarization in vitro. Conclusion The M2MMS links M2 macrophage–driven immune remodeling to breast cancer prognosis and provides a basis for risk stratification and mechanistic investigation. KLF4 represents a regulatory node in tumor–macrophage interaction in vitro; its role in vivo and the clinical utility of the M2MMS require further validation.
This study identified CMA-related cellular heterogeneity, established a molecular prognostic model that retained prognostic discrimination in two independent validation cohorts, demonstrated the functional relevance of KRT19, and developed an independent clinical prediction tool.
Qing-Yan Kou, Sheng-Qian Qiao, Zhen-Yuan Liu et al.· Frontiers in Cell and Develo...· 0 citations
It is suggested that SASP-related gene-expression patterns are associated with LUAD molecular subtypes, senescence signaling, computationally inferred immune features, and treatment-related outcomes and may serve as a potential biomarker for prognostic stratification in LUAD.
Background T cell-mediated tumor killing (TTK) is a central mechanism for antitumor immunity. However, the prognostic value of genes regulating TTK sensitivity (GSTTKs) in breast cancer (BC), along with their impact on the immune microenvironment and T-cell dynamics, remains to be systematically elucidated. Methods Usi...
Yu-Hao Zhu, Yi-Yun Chen, Jun-Dong Wu· International Journal of Wom...· 0 citations
Introduction Colorectal cancer (CRC) represents a major global health burden, marked by high morbidity and mortality rates that place a considerable strain on healthcare systems. Methods This study leveraged integrated bioinformatic analyses, single-cell RNA sequencing, and clinical sample validation to investigate the...
Hui Chen, Zhi-Peng Li, Zhen Lin et al.· Frontiers in Immunology· 0 citations
Background/Objectives: Myeloid-derived suppressor cells (MDSCs) play an essential role in tumor immune evasion from the immune system; however, the common molecular signatures associated with MDSCs across different cancer types remain limited. This study aimed to identify and validate common MDSC-associated hub genes a...
Maysa M. Abosenna, Ahmed Osman, Ahmed M. R. Fath El-Bab et al.· Immuno· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.